VANCENASE AQ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VANCENASE AQ (VANCENASE AQ).
Glucocorticoid receptor agonist; anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of arachidonic acid metabolites, and suppression of cytokine production.
| Metabolism | Hepatic metabolism via CYP3A4; extensive first-pass metabolism. |
| Excretion | Renal: minimal (<10% as unchanged drug); fecal: majority as metabolites via biliary excretion. |
| Half-life | Terminal elimination half-life: approximately 3 hours; clinical context: supports twice-daily dosing. |
| Protein binding | Approximately 87% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Vd: ~0.5 L/kg; indicates distribution into total body water. |
| Bioavailability | Intranasal: <0.1% systemic bioavailability due to low absorption and extensive first-pass metabolism. |
| Onset of Action | Intranasal: 12-24 hours for initial symptomatic relief. |
| Duration of Action | Duration: approximately 12 hours; clinical note: requires regular use for full therapeutic effect. |
| Molecular Weight | 521.04 |
1-2 sprays (50-100 mcg) per nostril twice daily (total daily dose 200-400 mcg).
| Dosage form | SPRAY, METERED |
| Renal impairment | No adjustment required. |
| Liver impairment | No adjustment required. |
| Pediatric use | Children 6-11 years: 1 spray (50 mcg) per nostril twice daily (total daily dose 200 mcg). Children 12 years and older: same as adults. |
| Geriatric use | Same as adult dosing; no specific adjustments. |
| 1st trimester | Limited human data; animal studies show no teratogenicity at therapeutic doses. Use only if clearly needed. |
| 2nd trimester | No known risks; minimal systemic absorption. Use cautiously if benefit outweighs risk. |
| 3rd trimester | Avoid chronic high doses; theoretical risk of fetal adrenal suppression with prolonged use. |
Clinical note
Comprehensive clinical and safety monograph for VANCENASE AQ (VANCENASE AQ).
| Placental transfer | Minimal; beclomethasone dipropionate has low placental transfer due to high protein binding and rapid metabolism. |
| Breastfeeding | Systemic absorption is minimal (<0.025% of nominal dose); unlikely to cause adverse effects in nursing infants. However, caution is advised with high doses or prolonged use. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to beclomethasone dipropionate or any componentUntreated fungal, bacterial, or viral infections of the nasal mucosa
| Precautions | Nasal irritation and epistaxis, Risk of localized Candida infections, Potential for growth suppression in children with prolonged use, Systemic corticosteroid effects with high doses or prolonged use, Avoid use in patients with untreated nasal mucosal infections |
| Food/Dietary | No clinically relevant food interactions. Take without regard to meals. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L2 (Safer) |
| Teratogenic Risk | Beclomethasone dipropionate (VANCENASE AQ) is classified as Pregnancy Category C. Systemic absorption following intranasal administration is minimal (<1%). No increased risk of major congenital malformations has been observed in human studies with inhaled or intranasal corticosteroids. However, animal studies with high systemic doses showed teratogenic effects. The risk to the fetus is considered low when used at recommended intranasal doses, but caution is advised during the first trimester. Potential for fetal hypothalamic-pituitary-adrenal axis suppression is theoretical but unlikely with intranasal use. |
| Fetal Monitoring | No specific maternal-fetal monitoring is required for VANCENASE AQ. Routine prenatal care is sufficient. In patients using high doses or with prolonged use, monitor for signs of adrenal suppression (e.g., fatigue, hypotension) though unlikely. Fetal growth and development should be assessed per standard obstetric guidelines. |
| Fertility Effects | Animal studies with high systemic doses of beclomethasone have shown impaired fertility (e.g., reduced conception rates, increased embryonic loss). However, at recommended intranasal doses, systemic exposure is minimal, and no adverse effects on human fertility are expected. Clinical data are insufficient to definitively exclude an effect. |
| VANCENASE AQ (beclomethasone dipropionate monohydrate) is an intranasal corticosteroid for allergic rhinitis. Onset of action is not immediate; regular use for several days to weeks is required for maximal effect. Priming the pump (5 actuations or until fine mist appears) is necessary before first use or after 7 days of non-use. Warn patients about epistaxis, nasal septal perforation (rare), and local fungal infections (Candida). Monitor for glaucoma and cataracts with long-term use. Not for acute exacerbations; adjunctive therapies may be needed. Systemic absorption is minimal at recommended doses but caution with concomitant strong CYP3A4 inhibitors. |
| Patient Advice | Use regularly every day; do not expect immediate relief. · Prime the nasal spray pump with 5 test sprays before first use or if unused for 7 days. · Blow nose gently before each use; insert nozzle into nostril, point away from septum, and spray while breathing lightly through nose. · Do not use for more than 6 weeks without consulting your doctor. · Common side effects include nosebleeds, nasal irritation, headache, and sore throat. · Seek medical attention if you experience vision changes, persistent nasal discomfort, or signs of infection. · Do not share the spray bottle with others. |